SPARC2024-01-012024-03-31 SPARC2024-01-012024-03-31 SPARC2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member SPARC2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member SPARC2024-01-012024-03-31in-bse-fin:OneOperatingExpenses03Member SPARC2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member SPARC2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member SPARC2024-01-012024-03-31in-bse-fin:FourOperatingExpenses03Member SPARC2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532872 SPARC NA Sun Pharma Advanced Research Company Limited Equity 2023-04-01 2024-03-31 2024-05-24 2024-05-17 INR Lakhs Yearly 16:30:00 20:00:00 2024-05-24 2024-05-24 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceutical Research and Development 2024-01-01 2024-03-31 Audited Consolidated 165600000.00 44000000.00 209600000.00 74600000.00 0.00 0.00 500300000.00 9100000.00 30700000.00 649000000.00 1263700000.00 -1054100000.00 0.00 -1054100000.00 16300000.00 -12500000.00 3800000.00 0.00 -1057900000.00 0.00 0.00 0.00 0.00 -1057900000.00 -8200000.00 -1066100000.00 0.00 0.00 324500000.00 1 -3.26 -3.26 0.00 0.00 -3.26 -3.26 1. These audited consolidated financial results relates to Sun Pharma Advanced Research Company Limited (the 'Company') and its Wholly Owned Subsidiary (together the ‘Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements . 2. The above audited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 24, 2024. 3. The above audited consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 4. The Company had formed a wholly owned subsidiary in USA named SPARCLIFE, Inc. on September 25, 2023. Hence consolidated financial results have been prepared from the quarter ended September 30, 2023. 5. During the quarter ended March 31, 2023, the Group had paused the development of SCO-120 program due to changing clinical landscape. Pursuant to this, the Group had made provision for committed costs for this program estimated amounting to 2,700 lakhs. During the quarter ended September 30, 2023, basis the final settlement, the Group reversed an excess provision of 324 lakhs. 6. The Group has incurred cash losses in past years and in the current year. However, the Group has unutilized credit limits from banks (which are guaranteed by its Promoter Group Entity) and from its promoter group entity, to support its operations. Further, the Group has also received a financial support letter from its Promoter Group Entity to ensure its status as Going Concern and the continuance of its operations, as and when required. 7. On April 10, 2024, the Group has intimated the results of interim analysis of PROSEEK study relating to Parkinson disease project (K0706). The study failed todemonstrate superiority of Vodobatinib in the pre-specified primary endpoint as compared to placebo. The Group plans to complete the full analysis of clinical outcomes and correlative biomarker data in the coming months. The Group believes that all impacts of this study on its financial statements, relevant for the year and quarter ended March 31, 2024 have been considered. 8. he Group has only one reportable business segment namely 'Pharmaceutical Research & Development'. 9. The figures for the quarter ended March 31, 2024 and March 31, 2023 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the relevant financial years which was subject to limited review by the Statutory Auditors of the Group. 10. Previous period figures have been regrouped / reclassified, wherever considered necessary. Single segment 2023-04-01 2024-03-31 Audited Consolidated 755500000.00 294700000.00 1050200000.00 281300000.00 0.00 0.00 1418400000.00 16900000.00 125100000.00 3076800000.00 4918500000.00 -3868300000.00 0.00 -3868300000.00 16300000.00 -12500000.00 3800000.00 0.00 -3872100000.00 0.00 0.00 0.00 0.00 -3872100000.00 2000000.00 -3870100000.00 0.00 0.00 324500000.00 1 4803200000.00 -11.93 -11.93 0.00 0.00 -11.93 -11.93 Clinical trial expenses / products development expense 224500000.00 Other expenses 130400000.00 Professional charges 294100000.00 Clinical trial expenses / products development expense 1013500000.00 Other expenses 538700000.00 Professional charges 1524600000.00 1073500000.00 12600000.00 0.00 0.00 1900000.00 425300000.00 0.00 0.00 0.00 0.00 0.00 254900000.00 254900000.00 12600000.00 675800000.00 2456600000.00 0.00 18000000.00 155300000.00 53300000.00 1500000000.00 2200000.00 427900000.00 2156700000.00 0.00 537100000.00 2693800000.00 5150400000.00 324500000.00 933000000.00 1257500000.00 1257500000.00 0.00 0.00 146900000.00 146900000.00 60500000.00 0.00 0.00 1035000000.00 1242400000.00 470000000.00 1422900000.00 468100000.00 2361000000.00 150600000.00 122400000.00 16500000.00 0.00 2650500000.00 3892900000.00 5150400000.00 16900000.00 0.00 152100000.00 0.00 -630900000.00 0.00 0.00 -31800000.00 0.00 -58900000.00 0.00 226500000.00 0.00 125100000.00 0.00 37800000.00 0.00 0.00 0.00 20600000.00 0.00 254700000.00 0.00 0.00 0.00 0.00 0.00 14700000.00 0.00 -382600000.00 -4250900000.00 0.00 0.00 0.00 41100000.00 0.00 -4292000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4900000.00 265100000.00 2841900000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 223700000.00 0.00 1109900000.00 0.00 3915300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 644200000.00 174600000.00 0.00 29400000.00 0.00 16000000.00 0.00 0.00 424200000.00 47500000.00 0.00 47500000.00 5800000.00 53300000.00 8300000.00 -1900000.00 -100000.00 -100000.00